The permeation of dynorphin A 1–6 across the blood brain barrier and its effect on bovine brain microvessel endothelial cell monolayer permeability

[1]  S. Lunte,et al.  Evaluation of an on-capillary copper complexation methodology for the investigation of in vitro metabolism of dynorphin A 1-17. , 2010, Journal of separation science.

[2]  Allison T. Knoll,et al.  Dynorphin, stress, and depression , 2010, Brain Research.

[3]  V. Haroutunian,et al.  Dysregulation of dynorphins in Alzheimer disease , 2007, Neurobiology of Aging.

[4]  P. Andrén,et al.  Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease. , 2005, Journal of mass spectrometry : JMS.

[5]  Masaaki Iwata,et al.  Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant‐like effects , 2004, Journal of neurochemistry.

[6]  B. Chait,et al.  Dynorphin A(1–17) biotransformation in striatum of freely moving rats using microdialysis and matrix‐assisted laser desorption/ionization mass spectrometry , 2003, Journal of neurochemistry.

[7]  D. Walker,et al.  Site and mechanism of action of dynorphin A-(1-13) and N-methyl-D-aspartate on ACTH release in fetal sheep. , 2002, American journal of physiology. Endocrinology and metabolism.

[8]  Jeffrey J. Jones,et al.  MATRIX-ASSISTED LASER DESORPTION MASS SPECTROMETRY , 2002 .

[9]  M Gumbleton,et al.  Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. , 2001, Journal of pharmaceutical sciences.

[10]  T. Vanderah,et al.  Neuropathic pain: the paradox of dynorphin. , 2001, Molecular interventions.

[11]  P. Knapp,et al.  Structure–Activity Analysis of Dynorphin A Toxicity in Spinal Cord Neurons: Intrinsic Neurotoxicity of Dynorphin A and Its Carboxyl-Terminal, Nonopioid Metabolites , 2001, Experimental Neurology.

[12]  B. Chait,et al.  Differential biotransformation of dynorphin A(1–17) and dynorphin A(1–13) peptides in human blood, ex vivo , 1996, Peptides.

[13]  B. Chait,et al.  In vitro biotransformation of dynorphin A (1-17) is similar in human and rhesus monkey blood as studied by matrix-assisted laser desorption/ionization mass spectrometry. , 1996, The Journal of pharmacology and experimental therapeutics.

[14]  K. Audus,et al.  Leucine enkephalin effects on paracellular and transcellular permeation pathways across brain microvessel endothelial cell monolayers. , 1994, Journal of cardiovascular pharmacology.

[15]  K. Audus,et al.  Leucine Enkephalin Effects on Brain Microvessel Endothelial Cell Monolayer Permeability , 1994, Pharmaceutical Research.

[16]  R. Oishi,et al.  Enhancement of blood-brain barrier permeability to sodium fluorescein by stimulation of µ opioid receptors in mice , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

[17]  W. Banks,et al.  Analgesia and the blood-brain barrier transport system for Tyr-MIF-1/enkephalins: Evidence for a dissociation , 1988, Neuropharmacology.

[18]  W. Banks,et al.  Tyr-MIF-1 and Met-enkephalin share a saturable blood-brain barrier transport system , 1987, Peptides.

[19]  W. Banks,et al.  Carrier-mediated transport of enkephalins and N-Tyr-MIF-1 across blood-brain barrier. , 1986, The American journal of physiology.

[20]  K. Audus,et al.  Characterization of an In Vitro Blood–Brain Barrier Model System for Studying Drug Transport and Metabolism , 1986, Pharmaceutical Research.

[21]  E. Hall,et al.  Pathobiology of dynorphins in trauma and disease. , 2005, Frontiers in bioscience : a journal and virtual library.